CHF 5074

Drug Profile

CHF 5074

Alternative Names: CHF-5074; CSP-1103

Latest Information Update: 21 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi
  • Class Antidementias; Biphenyl compounds; Cyclopropanes; Propionic acids; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Glial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mild cognitive impairment

Most Recent Events

  • 21 Mar 2016 CHF 5074 is still in phase II for Mild cognitive impairment due to Alzheimer’s disease in Italy and USA
  • 14 Jul 2015 CereSpir has patent protection for CHF 5074 in USA
  • 01 Jul 2015 CereSpir submits special protocol assessment request to the US FDA for a pivotal phase III trial for Mild cognitive impairment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top